TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.010
+0.120 (3.08%)
Mar 25, 2026, 4:00 PM EDT - Market closed

TriSalus Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
45.1529.4318.5112.4-
Revenue Growth (YoY)
53.41%58.99%49.31%--
Cost of Revenue
6.974.12.612.26-
Gross Profit
38.1925.3315.9110.14-
Selling, General & Admin
50.1743.8140.5525.223.04
Research & Development
14.9717.6929.8421.36-
Total Operating Expenses
65.1361.4970.3846.583.04
Operating Income
-26.95-36.17-54.48-36.44-3.04
Interest Income
0.560.40.430.180.06
Interest Expense
-5.54-3.09-0.02-0-
Other Non-Operating Income (Expense)
-7.298.81-5.29-10.927.74
Total Non-Operating Income (Expense)
-12.276.13-4.88-10.747.81
Pretax Income
-39.22-30.04-59.35-47.184.77
Provision for Income Taxes
-0.01-0.01-0.01-0.01-
Net Income
-69.69-33.23-63.6-50.024.77
Net Income Attributable to Preferred Dividends
-30.46-3.19-4.24-2.83-
Net Income to Common
-69.69-33.23-63.6-50.024.77
Shares Outstanding (Basic)
3825900
Shares Outstanding (Diluted)
3825900
Shares Change (YoY)
49.61%169.61%2934.71%41.31%-
EPS (Basic)
-1.84-1.31-6.77-161.55-131.65
EPS (Diluted)
-1.84-1.31-6.77-161.55-131.65
Free Cash Flow
-18.93-41.19-51.17-32.97-1.74
Free Cash Flow Per Share
-0.50-1.63-5.45-106.48-7.93
Gross Margin
84.57%86.06%85.93%81.79%-
Operating Margin
-59.68%-122.88%-294.28%-293.91%-
Profit Margin
-86.85%-102.05%-320.59%-380.46%-
FCF Margin
-41.93%-139.95%-276.41%-265.91%-
EBITDA
-26.32-35.42-53.79-36.04-3.04
EBITDA Margin
-58.29%-120.35%-290.59%-290.70%-
EBIT
-26.95-36.17-54.48-36.44-3.04
EBIT Margin
-59.68%-122.88%-294.28%-293.91%-
Effective Tax Rate
0.02%0.02%0.02%0.02%0.00%
Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q